Could a tiny dose of steroids help new arthritis patients?

NCT ID NCT07252271

Not yet recruiting Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether adding a very low dose of the steroid prednisolone (4 mg daily for 4 weeks, then tapering off) to standard treatment helps control symptoms in people newly diagnosed with active rheumatoid arthritis. About 112 adults will be randomly assigned to receive either prednisolone or a placebo for 12 weeks. The main goal is to see if the low-dose steroid improves disease activity scores at 4 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Prednisolone (a steroid) at 4 mg daily, then tapered off over 10 weeks
What this could lead to: If it works, this could offer a short-term, low-dose steroid option to quickly control symptoms in newly diagnosed rheumatoid arthritis patients.
What could go wrong: This is a small, early-phase trial with only 112 participants. The low dose may not provide significant benefit, and steroids carry risks like infection and bone thinning.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEMATOID ARTHRITIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.